Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting

Monica Javidnia; Mark Frasier; Ira Shoulson; Ibrahim Turkoz; Kumar Budur

Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting

Innov Clin Neurosci. 2020 Jan 1;17(1-3):14-19.

Authors

Monica Javidnia^{1

2

3

4

5}, Mark Frasier^{1

2

3

4

5}, Ira Shoulson^{1

2

3

4

5}, Ibrahim Turkoz^{1

2

3

4

5}, Kumar Budur^{1

2

3

4

5}

Affiliations

¹ Drs. Javidnia and Shoulson are with the Center for Health + Technology and the Department of Neurology, University of Rochester Medical Center in Rochester, New York.
² Dr. Shoulson is also with Grey Matter Technologies in Sarasota, Florida.
³ Dr. Frasier is with the Michael J. Fox Foundation for Parkinson's Research in New York, New York.
⁴ Dr. Turkoz is with Janssen Research & Development in Titusville, New Jersey.
⁵ Dr. Budur is with AbbVie in Lake Bluff, Illinois.

PMID: 32547841
PMCID: PMC7239563

Abstract

The International Society for Central Nervous System Clinical Trials and Methodology (ISCTM) partnered with the Michael J. Fox Foundation for Parkinson's Research to hold a joint session on innovation in Parkinson's disease research at the ISCTM 14th Annual Scientific Meeting held February 20 to 22, 2018 in Washington, D.C. The session focused on (1) biomarkers and outcomes measures in Parkinson's disease clinical trials; 2) clinical trial designs, outcomes, and statistical approaches; and 3) the path forward. This paper aims to summarize key takeaways from the session presenters, panelists, and audience members.

Keywords: Parkinson’s disease; RBD; disease modification; disease progression; prodromal.

Publication types

Review